In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (

在ADlong第三阶段b研究中，几乎所有接受EBGLYSS治疗的患者都实现了显著的皮肤改善 (

EASI

易学易用

-75) for up to four years

-75）最长四年

75% of patients achieved a high bar of near-complete skin clearance (

75%的患者达到了接近完全皮肤清除的高标准（

EASI

易学易用

-90) and 78% experienced significant itch relief (Pruritus NRS

-90）并且78%的患者获得了显著的瘙痒缓解（Pruritus NRS

≤

≤

4), one of the most bothersome symptoms for patients

4)，患者最烦人的症状之一

80% of patients achieved durable results without the need for topical corticosteroids

80%的患者在无需使用局部皮质类固醇的情况下获得了持久的效果。

INDIANAPOLIS

印第安纳波利斯

,

，

March 27, 2026

2026年3月27日

/PRNewswire/ -- New long-term data show

/PRNewswire/ -- 新的长期数据显示

Eli Lilly and Company's

礼来公司

(NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for patients with moderate-to-severe atopic dermatitis (eczema) in an open-label extension study offering once-monthly maintenance injection. Interim findings from the first year of the ADlong Phase 3b study will be presented at the .

（纽约证券交易所代码：LLY）EBGLYSS（lebrikizumab-lbkz）在一项开放标签扩展研究中，为中度至重度特应性皮炎（湿疹）患者提供了长达四年的持久皮肤清除和持续瘙痒缓解，该研究提供每月一次的维持注射。ADlong 第3b期研究第一年的中期结果将在会议上公布。

American Academy of Dermatology

美国皮肤病学会

(AAD) Annual Meeting, taking place

(AAD) 年会，正在举行

March 27-31

3月27日至31日

in

在

Denver

丹佛

.

。

1

1

'These data underscore our unwavering commitment to expanding what people with moderate-to-severe atopic dermatitis can achieve with treatment,' said

“这些数据强调了我们对扩大中度至重度特应性皮炎患者通过治疗所能实现的目标的坚定承诺，”

Adrienne Brown

阿德里安·布朗

, executive vice president and president, Lilly Immunology. 'For too long the focus has been around symptom management and many patients struggle to achieve consistent disease control despite cycling through topical treatments. EBGLYSS is helping transform this treatment paradigm—allowing people the opportunity to reimagine life without the frequent interruptions caused by flares or topicals applied 2-3 times per day.'.

，执行副总裁兼礼来免疫学总裁。“长期以来，重点一直放在症状管理上，尽管患者不断尝试局部治疗，但许多患者仍难以实现持续的疾病控制。EBGLYSS 正在帮助转变这种治疗模式——让人们有机会重新构想没有因病情发作或每天 2-3 次局部用药带来的频繁干扰的生活。”

EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity and slow dissociation rate.

EBGLYSS是一种白细胞介素-13（IL-13）抑制剂，能够以高结合亲和力和缓慢的解离速率选择性阻断IL-13信号传导。

2,3,4

2,3,4

The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.

细胞因子IL-13是特应性皮炎的主要细胞因子，驱动皮肤中的2型炎症循环，导致皮肤屏障功能障碍、瘙痒、皮肤增厚和感染。

5,6

5,6

In the ADlong study, the majority of patients achieved a high bar of near-complete skin clearance and significant itch relief with up to four years of continuous EBGLYSS treatment. Most patients (77%) were on EBGLYSS monotherapy, and 80% achieved results without topical corticosteroids. In addition, 80% achieved these outcomes with EBGLYSS monthly maintenance dosing during the study..

在ADlong研究中，大多数患者在接受长达四年的连续EBGLYSS治疗后，达到了接近完全的皮肤清除和显著的瘙痒缓解。大多数患者（77%）仅接受EBGLYSS单药治疗，80%的患者在没有使用局部皮质类固醇的情况下取得了效果。此外，在研究期间，80%的患者通过每月一次的EBGLYSS维持剂量达成了这些成果。

Efficacy results at up to four years of continuous treatment*

长达四年的连续治疗的有效性结果*

EASI

易学易用

-75**

-75**

94 %

94%

EASI

易学易用

-90

-90

†

†

75 %

75%

IGA 0,1

IGA 0.1

‡

‡

68 %

68 %

Pruritus NRS ≤4

瘙痒 NRS ≤4

§

§

78 %

78 %

* Data are reported as observed

* 数据按实际观测值报告

**

**

EASI

易学易用

=Eczema Area and Severity Index;

湿疹面积和严重程度指数；

EASI

易学易用

-75=75% reduction in

-75=减少75%

EASI

易学易用

from baseline

从基线

†

†

EASI

易学易用

-90=90% reduction in

-90=减少90%

EASI

易学易用

from baseline

从基线

‡ IGA 0,1=Investigator's Global Assessment 0 or 1 ('clear' or 'almost clear')

‡ IGA 0,1=研究者整体评估 0 或 1（“清除”或“几乎清除”）

§ Pruritus NRS=Numeric Rating Scale rating itch from 0-10 with 10 being worst imaginable itch within the past 24 hours

§ 瘙痒 NRS=数字评分量表，过去24小时内从0-10评分瘙痒程度，10为可想象的最严重瘙痒

The safety of EBGLYSS in the first year of the ADlong study was consistent with the known profile in patients with moderate-to-severe atopic dermatitis, regardless of dose frequency, and no new safety signals were observed. The majority of adverse events were mild or moderate and did not lead to discontinuation.

在ADlong研究的第一年中，EBGLYSS的安全性与已知的中重度特应性皮炎患者中的表现一致，且不依赖于剂量频率，未观察到新的安全性信号。大多数不良事件为轻度或中度，并未导致停药。

Reported treatment-related adverse events in the study included conjunctivitis (6.9%) and injection-site reactions (0.6%)..

研究中报告的与治疗相关的不良事件包括结膜炎 (6.9%) 和注射部位反应 (0.6%)。

The ADlong study is ongoing and will continue for an additional year of treatment. These results reinforce

ADlong 研究正在进行中，并将持续进行额外一年的治疗。这些结果进一步证实了

previously reported long-term results

以前报告的长期结果

for EBGLYSS for patients with moderate-to-severe atopic dermatitis. In addition, a post-hoc analysis presented at Maui Derm Hawaii 2026 on

针对中重度特应性皮炎患者的EBGLYSS。此外，一项在2026年毛伊岛皮肤科会议上展示的事后分析表明，

EASI

易学易用

-75 stable responders showed less than one flare per patient per year with EBGLYSS monthly maintenance dosing used as monotherapy.

-75名稳定应答者在使用EBGLYSS每月维持剂量作为单一疗法时，每年每名患者的病情复发少于一次。

7

7

'There is still an unmet need for people with moderate-to-severe atopic dermatitis who frequently experience unpredictable flares and are in need of treatment options that go beyond just symptomatic relief and address the underlying inflammation driving skin symptoms and persistent itch,' said

“对于中度至重度特应性皮炎患者，仍然存在未满足的需求，他们经常经历不可预测的病情发作，需要的治疗方案不仅要缓解症状，还要针对引发皮肤症状和持续瘙痒的根本炎症。”

Emma Guttman-Yassky

艾玛·古特曼-亚萨基

, M.D., Ph.D., The Waldman Professor and Health System Chair,

医学博士、哲学博士，沃尔德曼教授兼卫生系统主席，

Department of Dermatology

皮肤病学系

at the

在

Icahn School of Medicine at Mount Sinai

西奈山伊坎医学院

in

在

New York

纽约

. 'These four-year findings reinforce that EBGLYSS has the potential to deliver durable disease control, helping patients flare less with or without topicals.'

“这四项为期四年的研究结果进一步证实，EBGLYSS 有潜力提供持久的疾病控制，帮助患者减少使用或不使用外用药时的病情发作。”

Lilly continues to raise the standard of care in dermatology and boldly invest in the next wave of immunology innovation, which includes big bets on next-generation modalities, the targeted expansion of small molecules and advancing novel science that uncovers the potential of incretins. Lilly recently shared topline findings from the TOGETHER-PsA and TOGETHER-PsO trials investigating the concomitant use of ixekizumab and an incretin-based therapy to treat adults with psoriatic disease and obesity or overweight with at least one additional weight-related comorbid condition.

礼来继续提高皮肤病学的护理标准，并大胆投资于下一波免疫学创新，其中包括对下一代治疗模式的大胆押注、小分子的有针对性扩展以及推进揭示肠促胰岛素潜力的新科学。礼来最近分享了TOGETHER-PsA和TOGETHER-PsO试验的顶线结果，这些试验研究了ixekizumab与基于肠促胰岛素的疗法联合使用，以治疗患有银屑病和肥胖或超重且至少有一种其他与体重相关的合并症的成人患者。

Lilly's investigational therapies include DC-853, a novel oral IL-17 inhibitor being studied for psoriasis, and eltrekibart, a novel monoclonal antibody that targets neutrophil-driven inflammation and is being assessed in hidradenitis suppurativa..

礼来公司的在研疗法包括DC-853，一种正在研究用于治疗银屑病的新型口服IL-17抑制剂，以及eltrekibart，一种靶向中性粒细胞驱动炎症的新型单克隆抗体，正在被评估用于化脓性汗腺炎。

Lilly has exclusive rights for development and commercialization of EBGLYSS in the

礼来公司拥有 EBGLYSS 的独家开发和商业化权利。

U.S.

美国

and the rest of the world outside

而外界的其他地方

Europe

欧洲

. Lilly's partner Almirall has licensed the rights to develop and commercialize EBGLYSS for the treatment of dermatology indications, including atopic dermatitis, in

礼来公司的合作伙伴阿尔米拉尔已获得开发和商业化EBGLYSS用于治疗皮肤病适应症（包括特应性皮炎）的权利许可。

Europe

欧洲

.

。

About ADlong

关于ADlong

ADlong (

AD长（

NCT05916365

NCT05916365

) open-label extension study is evaluating the long-term safety and efficacy of EBGLYSS 250 mg dosed every four weeks (Q4W) in patients with moderate-to-severe atopic dermatitis for a total of 108 weeks. Adult and adolescent (ages 12–17, weighing ≥40 kg) patients from select countries in

）开放标签扩展研究正在评估EBGLYSS 250 mg每四周一次（Q4W）在中度至重度特应性皮炎患者中的长期安全性和有效性，总疗程为108周。来自选定国家的成人和青少年（12-17岁，体重≥40公斤）患者参与了此项研究。

Europe

欧洲

who completed the 100-week ADjoin extension study, including patients who completed the ADore trial (52 weeks), the ADhere trial (16 weeks), and Week 16 responders who completed the ADvocate 1 and 2 trials (52 weeks), were eligible to enroll in ADlong. Patients (N=174) in this analysis receive open-label EBGLYSS 250 mg Q4W, regardless of their previous treatment in ADjoin (Q2W or Q4W dose).

完成了为期100周的ADjoin扩展研究的患者，包括完成ADore试验（52周）、ADhere试验（16周）以及完成ADvocate 1和2试验（52周）的第16周应答者，均有资格注册参与ADlong。本分析中的患者（N=174）接受开放标签的EBGLYSS 250 mg Q4W治疗，无论他们之前在ADjoin中的治疗方案是Q2W还是Q4W剂量。

The approved maintenance dose of EBGLYSS is 250 mg once monthly, after taking EBGLYSS every two weeks for the four-month initial dosing phase (or later once achieving adequate clinical response)..

EBGLYSS 的批准维持剂量为每月一次 250 毫克，在最初的四个月初始剂量阶段（或在达到足够的临床反应后）每两周服用 EBGLYSS。

8

8

Intermittent use of topical rescue medications and short-term systemic treatments was allowed.

允许间歇性使用局部急救药物和短期系统治疗。

1

1

If response was below

如果响应低于

EASI

易学易用

-50, Q2W could be used and thereafter Q4W could be resumed.

-50，可以使用Q2W，之后可以恢复Q4W。

About EBGLYSS

关于EBGLYSS

EBGLYSS is a monoclonal antibody that selectively targets and neutralizes IL-13 with high binding affinity and a slow dissociation rate.

EBGLYSS是一种单克隆抗体，能够以高亲和力和缓慢的解离速度选择性地靶向并中和IL-13。

3,4,8

3，4，8

EBGLYSS binds to the IL-13 cytokine at an area that overlaps with the binding site of the IL-4Rα subunit of the IL-13Rα1/IL-4Rα heterodimer, preventing formation of this receptor complex and inhibiting IL-13 signaling. IL-13 is implicated as a primary cytokine tied to the pathophysiology of eczema, driving the type-2 inflammatory loop in the skin, and EBGLYSS selectively targets IL-13..

EBGLYSS结合到IL-13细胞因子的一个区域，该区域与IL-13Rα1/IL-4Rα异二聚体中IL-4Rα亚基的结合位点重叠，阻止该受体复合物的形成并抑制IL-13信号传导。IL-13被认为是一种与湿疹病理生理学相关的主要细胞因子，可驱动皮肤中的2型炎症循环，而EBGLYSS选择性靶向IL-13。

8

8

The EBGLYSS Phase 3 program in atopic dermatitis consists of seven key global studies evaluating over 1,600 patients, including two monotherapy studies (ADvocate 1 and 2), a combination study with topical corticosteroids (ADhere), long-term extension (ADjoin), adolescent open-label (ADore) and pediatric (ADorable 1 and 2) studies.

EBGLYSS在特应性皮炎的第三阶段项目包括七项关键的全球研究，评估了超过1600名患者，其中包括两项单药治疗研究（ADvocate 1和2）、一项与局部皮质类固醇联合使用的研究（ADhere）、长期扩展研究（ADjoin）、青少年开放标签研究（ADore）以及儿科研究（ADorable 1和2）。

EBGLYSS is also being studied in allergic rhinitis and chronic rhinosinusitis with nasal polyps..

EBGLYSS 还在过敏性鼻炎和伴鼻息肉的慢性鼻窦炎中进行研究。

EBGLYSS was approved in the

EBGLYSS 已获批

U.S.

美国

,

，

Japan

日本

and

和

Canada

加拿大

in 2024 and in the

2024年以及在

European Union

欧盟

in 2023. EBGLYSS is a first-line biologic treatment with the option of monotherapy that offers once-monthly maintenance dosing for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis that is not well controlled with topical prescription therapies..

在2023年。EBGLYSS 是一种一线生物治疗，可选择单药治疗，每月一次维持剂量，适用于12岁及以上、体重至少88磅（40公斤）、中度至重度特应性皮炎且局部处方疗法控制不佳的成人和儿童。

8

8

EBGLYSS 250 mg/2 mL injection is dosed as a single monthly maintenance injection following the initial phase of treatment. The recommended initial starting dose of EBGLYSS is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later when adequate clinical response is achieved; after this, maintenance dosing is a single monthly injection (250 mg every four weeks) which can be used with or without topical corticosteroids..

EBGLYSS 250 mg/2 mL 注射剂在初始治疗阶段后，作为单次每月维持注射使用。EBGLYSS 的推荐初始剂量为第 0 周和第 2 周时每次 500 mg（两次 250 mg 注射），随后每两周注射 250 mg，直至第 16 周或更晚达到充分临床反应；此后，维持剂量为每月一次单次注射（每四周 250 mg），可与局部皮质类固醇联合使用或单独使用。

8

8

Lilly is committed to serving patients living with moderate-to-severe atopic dermatitis and is working to enable broad first-line biologic access to EBGLYSS for patients not well controlled with topical prescription therapy through commercial insurance. Lilly has coverage with all three major national pharmacy benefit managers and 94% of commercially insured patients have coverage through national health plans.

礼来致力于为中重度特应性皮炎患者服务，并通过商业保险为那些使用局部处方治疗效果不佳的患者提供广泛的一线生物药物EBGLYSS的获取渠道。礼来已与三大全国性药房福利管理公司全面覆盖，94%的商业保险患者通过国家健康计划获得保障。

We have expanded Medicaid coverage and are pursuing similarly broad Medicare coverage as part of Lilly's health equity and affordability initiative. Through Lilly Support Services, Lilly offers a patient support program including co-pay assistance for eligible, commercially insured patients..

我们已经扩大了医疗补助覆盖范围，并且作为礼来公司健康公平与可负担性计划的一部分，我们正在追求同样广泛的医疗保险覆盖。通过礼来支持服务，礼来为符合条件的、商业保险的患者提供包括共付援助在内的患者支持计划。

INDICATION AND SAFETY SUMMARY

适应症与安全概述

EBGLYSS

EBGLYSS

®

®

(EHB-glihs) is an injectable medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies.

(EHB-glihs) 是一种注射药物，用于治疗 12 岁及以上、体重至少 88 磅（40 公斤）的中度至重度湿疹（特应性皮炎）成人和儿童患者，这些患者的病情通过局部（皮肤上使用的）处方疗法无法得到良好控制，或者无法使用局部疗法。

EBGLYSS can be used with or without topical corticosteroids..

EBGLYSS 可以与局部皮质类固醇一起使用，也可以单独使用。

It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg).

在年龄小于12岁的儿童或体重小于88磅（40公斤）的12岁至未满18岁儿童中，尚不清楚EBGLYSS是否安全有效。

Warnings - Do not use

警告 - 不要使用

EBGLYSS

EBGLYSS

if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients.

如果您对莱布立珠单抗-lbkz或EBGLYSS中的任何成分过敏。请参阅随EBGLYSS提供的患者信息说明书，以获取完整的成分列表。

Before using

使用前

Before using EBGLYSS, tell your healthcare provider about all your medical conditions, including if you:

在使用 EBGLYSS 之前，请告诉您的医疗保健提供者您的所有健康状况，包括您是否：

Have a parasitic (helminth) infection.

患有寄生虫（蠕虫）感染。

Are scheduled to receive any vaccinations. You should not receive a 'live vaccine' if you are treated with EBGLYSS.

计划接种任何疫苗。如果您正在使用EBGLYSS进行治疗，则不应接种“活疫苗”。

Are pregnant or plan to become pregnant. It is not known if EBGLYSS will harm your unborn baby. If you become pregnant during treatment with EBGLYSS, you or your healthcare provider can call

怀孕或计划怀孕。目前尚不清楚EBGLYSS是否会伤害您未出生的宝宝。如果您在使用EBGLYSS治疗期间怀孕，您或您的医疗保健提供者可以致电

Eli Lilly and Company

礼来公司

at 1-800-LillyRx (1-800-545-5979) to report the pregnancy.

拨打1-800-LillyRx（1-800-545-5979）报告怀孕情况。

Are breastfeeding or plan to breastfeed. It is not known if EBGLYSS passes into your breast milk.

正在哺乳或计划哺乳。 目前尚不清楚EBGLYSS是否会进入您的母乳中。

Tell your healthcare provider about all the medicines you take

告诉您的医疗保健提供者您所服用的所有药物

, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

，包括处方药和非处方药、维生素以及草本补充剂。

Possible side effects

可能的副作用

EBGLYSS can cause serious side effects, including:

EBGLYSS可能会引起严重的副作用，包括：

Allergic reactions. EBGLYSS can cause allergic reactions that may sometimes be severe.

过敏反应。EBGLYSS 可能会引起有时可能很严重的过敏反应。

Stop using EBGLYSS and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms:

如果出现以下任何症状，请立即停止使用EBGLYSS，并告知您的医疗保健提供者或寻求紧急帮助：

breathing problems or wheezing

呼吸困难或喘息

swelling of the face, lips, mouth, tongue or throat

面部、嘴唇、口腔、舌头或喉咙肿胀

hives

蜂巢

itching

瘙痒

fainting, dizziness, feeling lightheaded

昏厥、头晕、感觉头重脚轻

skin rash

皮疹

cramps in your stomach area (abdomen)

腹部（腹腔）绞痛

Eye problems.

眼部问题。

Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision.

如果您有任何新的或恶化的眼部问题，包括眼痛或视力变化（如视力模糊），请告知您的医疗保健提供者。

The most common side effects of EBGLYSS include:

EBGLYSS最常见的副作用包括：

eye and eyelid inflammation, including redness, swelling, and itching

眼睛和眼睑炎症，包括发红、肿胀和瘙痒

injection site reactions

注射部位反应

shingles (herpes zoster)

带状疱疹

These are not all of the possible side effects of EBGLYSS.

这些并非 EBGLYSS 的所有可能副作用。

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or

如需了解有关副作用的医疗建议，请咨询您的医生。您可以致电1-800-FDA-1088向FDA报告副作用，或者

www.fda.gov/medwatch

www.fda.gov/medwatch

.

。

How to take

如何服用

See the detailed 'Instructions for Use' that comes with EBGLYSS for information about how to prepare and inject EBGLYSS and how to properly store and throw away (dispose of) used EBGLYSS prefilled pens and prefilled syringes.

请参阅随 EBGLYSS 一起提供的详细“使用说明”，了解如何准备和注射 EBGLYSS，以及如何正确存放和丢弃（处理）已使用的 EBGLYSS 预填充笔和预填充注射器。

Use EBGLYSS exactly as prescribed by your healthcare provider.

请严格按照您的医疗保健提供者的处方使用EBGLYSS。

EBGLYSS is given as an injection under the skin (subcutaneous injection).

EBGLYSS 通过皮下注射给药。

If your healthcare provider decides that you or a caregiver can give the injections of EBGLYSS, you or a caregiver should receive training on the right way to prepare and inject EBGLYSS. Do not try to inject EBGLYSS until you have been shown the right way by your healthcare provider. In children 12 years of age and older, EBGLYSS should be given by a caregiver..

如果您的医疗保健提供者决定您或护理人员可以注射EBGLYSS，则您或护理人员应接受关于正确准备和注射EBGLYSS的培训。在您的医疗保健提供者向您展示正确方法之前，请勿尝试注射EBGLYSS。对于12岁及以上的儿童，EBGLYSS应由护理人员给予。

If you miss a dose of EBGLYSS, inject the missed dose as soon as possible, then inject your next dose at your regular scheduled time.

如果您错过了注射EBGLYSS，尽快补注射错过的剂量，然后在常规预定时间注射下一剂。

Learn more

了解更多

EBGLYSS is a prescription medicine available as a 250 mg/2 mL injection prefilled pen or prefilled syringe. For more information, call

EBGLYSS 是一种处方药，有 250 毫克/2 毫升注射预填充笔或预填充注射器两种形式。欲了解更多信息，请拨打

1-800-545-5979

1-800-545-5979

or go to

或前往

ebglyss.lilly.com

ebglyss.lilly.com

This summary provides basic information about EBGLYSS but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking to your doctor. Be sure to talk to your doctor or other healthcare provider about EBGLYSS and how to take it.

本摘要提供了有关 EBGLYSS 的基本信息，但并未包含有关此药物的所有信息。每次配药时，请务必阅读随处方提供的信息。此信息不能代替与医生的沟通。务必与您的医生或其他医疗保健提供者讨论 EBGLYSS 及其用法。

Your doctor is the best person to help you decide if EBGLYSS is right for you..

您的医生是帮助您确定 EBGLYSS 是否适合您的最佳人选。

LK CON BS

LK CON BS

AD APP

广告应用

EBGLYSS®, its delivery device base, and Lilly Support Services™ are trademarks owned or licensed by

EBGLYSS®、其输送装置底座和Lilly Support Services™ 是由

Eli Lilly and Company

礼来公司

, its subsidiaries, or affiliates.

，其子公司或附属公司。

About Lilly

关于Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

礼来是一家医药公司，将科学转化为治疗手段，致力于改善世界各地人们的生活。近150年来，我们一直是改变生命的发现的先驱，如今我们的药物正在帮助全球各地的人们。通过利用生物技术、化学和基因医学的力量，我们的科学家正在加速推进新的发现，以解决一些全球最重要的健康挑战：重新定义糖尿病护理；治疗肥胖症并遏制其最具破坏性的长期影响；推动对抗阿尔茨海默病的斗争；为一些最严重的免疫系统疾病提供解决方案；并将最难治疗的癌症转变为可管理的疾病。

With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit .

每迈向更健康的世界一步，我们都受到一个目标的激励：让数百万人的生活更美好。这包括开展反映世界多样性的创新临床试验，并努力确保我们的药物可及且负担得起。欲了解更多信息，请访问。

Lilly.com

莉莉网

and

和

Lilly.com/news

Lilly.com/新闻

, or follow us on

，或者关注我们

Facebook

脸书

,

，

Instagram

Instagram

and

和

LinkedIn

领英

. P-LLY

. P-LLY

Trademarks and

商标和

Trade Names

商标名称

All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto.

本新闻稿中提到的所有商标或商号均为公司财产，或者，若涉及属于其他公司的商标或商号，则为其各自所有者的财产。仅为方便起见，本新闻稿中提及的商标和商号未附带®和™符号，但此类引用不应被解释为表明公司或在适用情况下其各自所有者不会根据适用法律最大限度地主张公司或其对该等权利的所有权。

We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies..

我们无意通过使用或展示其他公司的商标和商号来暗示我们与其他公司存在关联，或受到其他公司的认可或赞助。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的警示声明

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about EBGLYSS (lebrikizumab-lbkz) as a treatment for patients with moderate-to severe atopic dermatitis and the timeline for future readouts, presentations, and other milestones relating to EBGLYSS and its clinical trials and reflects Lilly's current beliefs and expectations.

本新闻稿包含前瞻性声明（该术语定义见1995年《私人证券诉讼改革法案》），涉及EBGLYSS（lebrikizumab-lbkz）作为中至重度特应性皮炎患者的治疗方案，以及与EBGLYSS及其临床试验相关的未来数据发布、展示和其他里程碑的时间表，反映了礼来公司当前的信念和预期。

However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with the results to date or that EBGLYSS will receive additional regulatory approvals, or that it will be commercially successful.

然而，与任何医药产品一样，药物的研发和商业化过程中存在重大风险和不确定性。其中，不能保证未来的研究结果会与迄今为止的结果一致，也不能保证EBGLYSS会获得更多的监管批准，或者它会在商业上取得成功。

For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the .

有关这些可能导致实际结果与礼来公司预期不同的风险和其他不确定性的进一步讨论，请参阅礼来公司向美国证券交易委员会提交的Form 10-K和Form 10-Q报告。

United States Securities and Exchange Commission

美国证券交易委员会

. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

除非法律要求，礼来公司没有义务更新前瞻性声明以反映本发布日期之后的事件。

1

1

Weidinger S, et al. Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis: first year of ADlong Long-Term Extension Trial.

Weidinger S.等人。Lebrikizumab在中度至重度特应性皮炎患者中的疗效和安全性可维持长达4年：ADlong长期扩展试验的第一年。

American Academy of Dermatology

美国皮肤病学会

Annual Meeting.

年度会议。

March 2026

2026年3月

2

2

Simpson EL, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11. doi:10.1016/j.jaad.2018.01.017.

辛普森 EL 等。Lebrikizumab（一种抗IL-13单克隆抗体）在局部皮质类固醇控制不佳的中重度特应性皮炎成人患者中的疗效与安全性：一项随机、安慰剂对照的II期试验（TREBLE）。《美国皮肤病学会杂志》。2018；78（5）：863-871.e11。doi:10.1016/j.jaad.2018.01.017。

3

3

Okragly A, et al. Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. Dermatol Ther (Heidelb). 2023;13(7):1535-1547. doi:10.1007/s13555-023-00947-7

Okragly A, 等。白细胞介素-13抗体Lebrikizumab的结合、中和与内化。《皮肤病治疗学》（海德堡）。2023；13(7):1535-1547。doi:10.1007/s13555-023-00947-7

4

4

Ultsch M, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425(8):1330-1339. doi:10.10116/j.jmb.2013.01.024

乌尔奇 M 等。抗IL-13抗体Lebrikizumab对信号阻断的结构基础。《分子生物学杂志》。2013；425（8）：1330-1339。doi:10.10116/j.jmb.2013.01.024

5

5

Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi:10.1111/all.13954

比伯 T. 白细胞介素-13：在特应性皮炎中针对一种被低估的细胞因子。《过敏》。2020；75（1）：54-62。doi:10.1111/all.13954

6

6

Tsoi LC, et al. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J Invest Dermatol. 2019;139(7):1480-1489. doi:10.1016/j.jid.2018.12.018

崔LC等。特应性皮炎是一种以IL-13为主的疾病，与银屑病相比具有更大的分子异质性。《皮肤病学研究杂志》。2019;139(7):1480-1489。doi:10.1016/j.jid.2018.12.018

7

7

Merola J, et al. Patients with Atopic Dermatitis with a Stable Response to Lebrikizumab Flare Less in a Long-Term Study: A Post-hoc Analysis of the ADjoin Study. Maui Derm Hawaii.

Merola J, 等。在长期研究中，对莱布立珠单抗有稳定反应的特应性皮炎患者复发较少：ADjoin研究的事后分析。毛伊岛皮肤科夏威夷。

January 2026

2026年1月

8

8

EBGLYSS. Prescribing Information.

EBGLYSS。处方信息。

Lilly USA, LLC

美国礼来公司

.

。

Refer to:

参考：

Kelly Hoffman;

凯莉·霍夫曼；

kelly.hoffman@lilly.com

凯莉·霍夫曼@礼来公司.com

; 765-736-2555 (Lilly media)

；765-736-2555（礼来媒体）

Michael Czapar;

迈克尔·查帕尔；

czapar_michael_c@lilly.com

czapar_michael_c@lilly.com

; 317-617-0983 (Investors)

；317-617-0983（投资者）

View original content to download multimedia:

查看原始内容以下载多媒体：

https://www.prnewswire.com/news-releases/lillys-ebglyss-lebrikizumab-lbkz-delivered-up-to-four-years-of-durable-disease-control-for-patients-with-moderate-to-severe-atopic-dermatitis-302727205.html

https://www.prnewswire.com/news-releases/lillys-ebglyss-lebrikizumab-lbkz-为中度至重度特应性皮炎患者提供了长达四年的持久疾病控制-302727205.html

SOURCE

源代码

Eli Lilly and Company

礼来公司